Every claim, every source.

This is the first supervised controlled-feeding trial designed specifically to isolate intermittent fasting's metabolic effects from weight loss. Men with prediabetes were enrolled in a randomized crossover trial: 5 weeks of early time-restricted feeding (eTRF — a 6-hour eating window, with the last meal before 3 p.m.), followed by 5 weeks of a control schedule (12-hour eating window), then crossover. Critically, participants were fed enough food to maintain their weight in both conditions — the eating window changed, but total energy intake did not. Even without weight loss, eTRF improved insulin sensitivity, beta-cell responsiveness, systolic and diastolic blood pressure, oxidative stress (8-isoprostane), and evening appetite. The improvements demonstrate that intermittent fasting's cardiometabolic benefits are not solely mediated by weight loss — circadian alignment of eating and the duration of the daily fasting window have independent effects. The paper has been highly influential because it isolated the eating-window mechanism from the calorie-deficit mechanism.

This 12-week randomized trial compared a carbohydrate-restricted diet (12 percent carb / 59 percent fat / 28 percent protein) with a low-fat diet (56 percent carb / 24 percent fat / 20 percent protein) in 40 adults with atherogenic dyslipidemia — the metabolic-syndrome phenotype defined by high triglycerides, low HDL, central adiposity, and insulin resistance. Both diets were calorie-restricted to similar levels. Both produced improvements, but the carbohydrate-restricted arm consistently outperformed the low-fat arm across nearly every endpoint that defines metabolic syndrome. Glucose dropped 12 percent in the carb-restricted group; insulin fell 50 percent; insulin sensitivity improved 55 percent; body weight dropped 10 percent; adiposity dropped 14 percent. The lipid panel was the most striking divergence: triglycerides fell 51 percent on carb restriction (versus a smaller drop on low-fat), HDL rose 13 percent (versus no change), and the total-cholesterol-to-HDL ratio improved 14 percent more on carb restriction. The paper's interpretation is that the metabolic syndrome is fundamentally a carbohydrate-intolerance phenotype, and that restricting carbs addresses the upstream driver more directly than restricting fat does.

This is the conceptual paper that reframed type-2 diabetes from "irreversible chronic disease" to "the result of two reinforcing fat-accumulation cycles, each of which is reversible." Roy Taylor — invited to write the paper after presenting the hypothesis at Diabetes UK's Annual Scientific Meeting — argues that excess calorie intake drives liver fat accumulation, which causes insulin resistance and overproduction of glucose by the liver, which raises insulin secretion, which drives more fat storage in the pancreas, which damages beta cells and impairs insulin secretion. The two cycles (liver fat and pancreas fat) reinforce each other, but neither is structurally permanent. Sufficient sustained negative energy balance — typically the kind achieved by very-low-calorie diets — depletes both fat depots, breaks both cycles, and restores normal glucose handling. The hypothesis predicted what the DiRECT trial (Lean 2018) and Taylor's own Counterpoint study would later demonstrate experimentally: T2D reversal is achievable through weight loss alone, in primary care, without bariatric surgery.